Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Safety assessed by Adverse Events (AEs)

An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom,or disease (new or exacerbated) temporally associated with the use of a medicinal product.

Time frame: Approximately 24 months

Safety assessed by incidence of serious adverse events (SAE)

Adverse Event (AE) is considered "serious" if the investigator or sponsor view any of the following outcomes: Death, life-threatening, persistent or significant disability/incapacity, congenital anomaly or birth defect,hospitalization, or medically important event.

Time frame: Approximately 24 months

Number of participants with laboratory value abnormalities

Number of participants with potentially clinically significant laboratory values.

Time frame: Approximately 24 months

Duration of Response (DOR)

DOR is defined as the time from the date of the first response (CR/PR) until the date of radiological progressive disease or death due to any cause (whichever occurs first).

Time frame: Approximately 24 months

Progression Free Survival(PFS)

PFS is defined as the duration from the subject's first dose of the investigational product to the first imaging confirmation of radiological progressive disease or death due to any cause (whichever occurs first).